GLP-1 for PCOS: Does It Help?

Research-informed explainer — last updated 2026-04-11

GLP-1 receptor agonists are not FDA-approved for polycystic ovary syndrome, but the evidence supporting their off-label use is growing fast. In women with PCOS who carry excess weight and show signs of insulin resistance — which describes the majority of women with the condition — GLP-1 medications target the underlying metabolic dysfunction that drives irregular periods, elevated androgens, acne, and difficulty conceiving. Endocrinologists who specialize in metabolic disease are increasingly prescribing them, and dedicated clinical trials in PCOS are underway.

What PCOS is and why insulin resistance is central to it

Polycystic ovary syndrome is one of the most common endocrine disorders in women of reproductive age, affecting an estimated 8 to 13 percent of women worldwide. Despite its name, the defining feature is not cysts — it is a hormonal imbalance driven largely by insulin resistance and androgen excess.

The core biology works like this: when the body becomes resistant to insulin, the pancreas compensates by secreting more of it. Elevated circulating insulin has a direct stimulating effect on the ovaries, prompting them to produce excess testosterone and other androgens. That androgen excess suppresses the hormonal signaling needed to trigger ovulation. The result is irregular or absent menstrual cycles, and the constellation of symptoms that follow — acne, hirsutism (unwanted hair growth), and, for women trying to conceive, infertility.

Excess weight worsens insulin resistance, which worsens androgen production, which worsens anovulation. The cycle is self-reinforcing. Visceral adiposity — fat stored around the abdominal organs — is particularly implicated, as it drives the hepatic insulin resistance that underlies much of the metabolic dysfunction in PCOS. Roughly 50 to 80 percent of women with PCOS have overweight or obesity, and many also have non-alcoholic fatty liver disease, a condition that shares the same insulin resistance pathways.

How GLP-1 medications address the root cause

GLP-1 receptor agonists — medications like semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda) — work by mimicking a hormone the gut naturally releases after eating. They enhance insulin secretion in response to glucose, suppress glucagon, slow gastric emptying, and reduce appetite by acting on satiety centers in the brain. The net result is reduced food intake, weight loss, and — critically for PCOS — improved insulin sensitivity.

This matters because GLP-1 therapy does not merely treat the consequences of insulin resistance; it interrupts the mechanism. By reducing hyperinsulinemia, GLP-1 medications take the stimulus off the ovaries. Small studies have shown improvements in menstrual regularity, reductions in testosterone levels, and improved ovulation rates in women with PCOS treated with GLP-1 agonists. The effect is both metabolic and reproductive.

The visceral and hepatic components are also directly addressed. Research by Kenneth Cusi at the University of Florida has demonstrated that GLP-1 receptor agonists reduce liver fat and improve hepatic insulin resistance — the same pathways implicated in PCOS-related metabolic dysfunction [5, 6]. His work on the shared mechanisms of insulin resistance in non-alcoholic fatty liver disease provides a mechanistic framework for understanding why GLP-1s can improve PCOS-related metabolic markers even in women who do not have overt diabetes.

Weight loss evidence applicable to PCOS

The most rigorous data on GLP-1 and weight loss come from large phase 3 trials designed primarily for obesity and type 2 diabetes — not PCOS specifically. But the trial populations overlap substantially with women who have PCOS.

The STEP 1 trial, published in the New England Journal of Medicine in 2021, enrolled adults with overweight or obesity and demonstrated that semaglutide 2.4 mg weekly produced a mean weight reduction of 14.9 percent over 68 weeks — more than three times the weight loss seen with lifestyle intervention alone [1]. Women were well-represented in the trial, and many participants had the insulin resistance phenotype characteristic of PCOS. The magnitude of weight loss achieved is clinically meaningful for PCOS: a 5 to 10 percent reduction in body weight has been associated with significant improvements in cardiovascular risk factors in insulin-resistant individuals with type 2 diabetes [3, 4], and similar metabolic improvements are observed in PCOS.

The STEP 2 trial, led by Ildiko Lingvay at UT Southwestern and published in The Lancet, extended this work to adults with type 2 diabetes — a population with deep overlap in insulin resistance phenotype with PCOS — and showed 9.6 percent mean weight reduction with semaglutide 2.4 mg [2]. Improvements in glycemic control and insulin sensitivity accompanied the weight loss. These findings are directly relevant: if GLP-1 therapy can meaningfully improve insulin sensitivity in women with established type 2 diabetes, the same mechanism applies to the insulin resistance that defines metabolic PCOS.

It is important to be precise about what these trials do and do not show. They were not designed to study PCOS. They do not report outcomes like menstrual regularity, testosterone levels, or ovulation rates. The inference to PCOS is mechanistic and population-based, not a direct RCT finding in PCOS women. That distinction matters for informed decision-making.

Direct evidence in PCOS: limited but accumulating

Dedicated trials of GLP-1 receptor agonists in PCOS are smaller and fewer than the obesity literature, but they point in a consistent direction. Studies of liraglutide in PCOS have shown reductions in body weight, improvements in menstrual cycle regularity, decreases in free testosterone, and improved ovulation rates compared to placebo or metformin alone. Combination regimens — GLP-1 plus metformin — appear more effective than either agent alone in improving both metabolic and reproductive outcomes in PCOS.

Semaglutide-specific trials in PCOS are ongoing. Given the substantially greater weight loss achieved with semaglutide compared to liraglutide in head-to-head comparisons, and given that weight loss magnitude predicts improvement in PCOS hormonal parameters, the endocrinology community anticipates that semaglutide data will show larger reproductive benefits as well. The evidence base is still maturing, but the mechanistic rationale is strong and the early data are favorable.

How GLP-1 compares to metformin for PCOS

Metformin has been used off-label for PCOS insulin resistance for decades and remains the most commonly prescribed medication for metabolic PCOS in clinical practice. It improves insulin sensitivity primarily through inhibition of hepatic glucose output, reduces androgen levels modestly, and can improve menstrual regularity. It is generic, inexpensive, and has a long safety record.

GLP-1 receptor agonists differ in several important ways. They produce substantially more weight loss than metformin, which itself has modest effects on body weight. The weight loss from GLP-1 therapy drives additional improvements in insulin sensitivity beyond the direct pharmacologic effect — a compound benefit that metformin does not replicate. For women with significant obesity and PCOS, the greater weight loss may translate to more durable improvements in hormonal parameters.

The tradeoff is cost, access, and side effects. GLP-1 medications are expensive and often require prior authorization. Gastrointestinal side effects — nausea, vomiting, delayed gastric emptying — are common, particularly during dose escalation, and some women cannot tolerate them. Metformin's own GI side effects are well-documented but generally milder and often resolve over time.

Current endocrinology practice tends to use metformin as first-line for metabolic PCOS, adding or substituting a GLP-1 agonist when metformin is insufficient, when weight loss is a primary treatment goal, or when insulin resistance is severe. Neither agent is FDA-approved for PCOS, and the choice should be individualized.

Fertility considerations

Women with PCOS who are trying to conceive need specific guidance before starting a GLP-1 receptor agonist. Semaglutide and other GLP-1 medications are not approved for use in pregnancy, and current prescribing guidance recommends discontinuing them at least two months before attempting conception.

That said, there is an important distinction between short-term and long-term fertility effects. GLP-1 therapy that improves ovulation regularity may improve fertility for women with PCOS-related anovulatory infertility — but the medication itself should not be used during pregnancy. The clinical approach for women actively trying to conceive typically involves GLP-1 therapy as a pre-conception intervention: using it to restore metabolic function, improve ovulation, and reduce weight, then stopping before attempting pregnancy.

For women not currently seeking pregnancy, improving metabolic function with GLP-1 therapy can reduce the long-term reproductive consequences of untreated PCOS. Earlier restoration of regular ovulatory cycles may preserve ovarian reserve better than years of chronic anovulation. This is an area where endocrinology, reproductive endocrinology, and gynecology intersect, and a coordinated approach between specialists is often appropriate.

Who is a candidate

Not every woman with PCOS is a candidate for GLP-1 therapy. The strongest case exists when several factors are present:

Significant insulin resistance, evidenced by fasting insulin levels, HOMA-IR calculation, or indirect markers like acanthosis nigricans, dyslipidemia, or impaired fasting glucose.

Overweight or obesity, particularly with central adiposity. The greatest metabolic benefit from GLP-1 therapy accrues in women with a BMI above 27. For women with PCOS at a normal weight, the evidence base is thinner and the benefit-risk calculation is different.

Inadequate response to lifestyle modification and metformin. Most endocrinologists reserve GLP-1 therapy for women who have not achieved adequate metabolic improvement with first-line approaches, though this threshold is shifting as the weight loss data matures.

Elevated cardiovascular risk. Women with PCOS have elevated lifetime cardiovascular risk from chronic insulin resistance, dyslipidemia, and hypertension. GLP-1 medications have demonstrated cardiovascular risk reduction in trials of diabetic patients with established cardiovascular disease, and this benefit is plausible in the PCOS population as well.

Women with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not use GLP-1 receptor agonists. Pancreatitis history requires careful evaluation. Pregnancy and planned near-term conception are contraindications to active use.

Questions to ask your endocrinologist

• Do I have insulin resistance, and how severe is it? What tests have been done to assess it?
• Am I a candidate for GLP-1 therapy given my BMI, metabolic profile, and PCOS symptoms?
• Should I try or continue metformin before adding a GLP-1 agonist, or would combination therapy be appropriate?
• If I want to get pregnant in the next one to two years, how should GLP-1 therapy be timed relative to trying to conceive?
• What GLP-1 medication and dose would you recommend, and what side effects should I anticipate?
• How will we monitor my response — weight, menstrual cycle regularity, testosterone levels, insulin markers?
• Are there clinical trials in PCOS for GLP-1 medications that I might be eligible for?

The bottom line

GLP-1 receptor agonists are not a PCOS-specific treatment — there is no FDA-approved medication for PCOS itself. But they target the insulin resistance and excess weight that drive the hormonal dysfunction underlying most PCOS symptoms. Large phase 3 trials in obesity and type 2 diabetes document the magnitude of weight loss and insulin sensitivity improvement that is achievable [1, 2], and mechanistic research on hepatic insulin resistance confirms that GLP-1 therapy addresses the metabolic pathways shared by PCOS, fatty liver disease, and type 2 diabetes [5, 6]. Earlier evidence that even modest weight loss significantly improves cardiovascular and metabolic risk factors in insulin-resistant individuals [3, 4] reinforces the relevance of this drug class to PCOS management.

The dedicated PCOS trial data are still developing. Women considering GLP-1 therapy for PCOS deserve an honest account of what is well-established — the weight loss and insulin-sensitizing effects — and what remains under investigation — the direct reproductive outcomes in PCOS-specific populations. An endocrinologist with expertise in metabolic disease and PCOS can help weigh that evidence against your individual clinical picture and goals.